Posts With Tag Diabetes Treatment

Showing 1 - 3 of 3 Posts

$NLSP

•

Form 6-K

•

2025-02-25

Last updated: 3 months ago

NLS Pharmaceutics Ltd. February 2025 Form 6-K: Key FDA Meeting Insights

Explore NLS Pharmaceutics Ltd.'s February 2025 Form 6-K detailing FDA meeting success for Type 1 Diabetes treatment, showcasing regulatory progress and company compliance.

NLS Pharmaceutics Type 1 Diabetes Treatment FDA Approval Pharmaceutical Industry Clinical Development

$NLSP

•

Form 6-K

•

2025-02-10

Last updated: 4 months ago

NLS Pharmaceutics Ltd. February 2025 Report: New Diabetes Treatment Strategy Unveiled

Explore NLS Pharmaceutics Ltd.'s latest 6-K report detailing a strategic partnership with Kadimastem for innovative diabetes therapies beyond GLP-1. Key insights included.

NLS Pharmaceutics Diabetes Treatment Healthcare Innovation GLP-1 Therapies Pharmaceutical Partnerships

$NLSP

•

Form 6-K

•

2024-12-19

Last updated: 6 months ago

NLS Pharmaceutics Ltd. Form 6-K: December 2024 Report on FDA Pre-IND Meeting Submission

Explore NLS Pharmaceutics' December 2024 report detailing FDA Pre-IND meeting request for Type 1 Diabetes treatment. Discover key developments and strategic insights.

NLS Pharmaceutics Type 1 Diabetes Treatment FDA Pre-IND Meeting Biopharmaceutical Industry Innovative Therapies